Marksans Pharma Share Price Target 2024, 2025, 2026 To 2030

Marksans Pharma, a prominent player in the pharmaceutical industry, specializes in formulating prescription and over-the-counter drugs across key therapeutic segments including Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, and Gynaecology.

In this article, we will comprehensively explore Marksans Pharma, discussing its history, operational scope, focus areas, achievements, and impactful contributions to healthcare. Join us as we uncover all aspects of Marksans Pharma and its significant presence in the medical field.

About Marksans Pharma

Marksans Pharma’s revenue mix in FY23 reflects a diversified portfolio across various therapeutic segments. The highest revenue contribution came from Pain Management products at 44%, followed by Cough & Cold remedies at 14%, and Cardiovascular System medications at 9%. The company’s focus on Over the Counter (OTC) products intensified, with OTC revenue accounting for approximately 74% in FY23, up from 69% in FY22, while Prescription (RX) revenue decreased to around 26% in FY23 from 31% in FY22.

Geographically, the revenue split for H1FY24 shows a significant presence in the US & North America (40%), Europe & UK (45%), and smaller contributions from Australia & Canada (10%) and the Rest of the World (5%).

Marksans Pharma boasts a robust product portfolio comprising over 1500 Stock Keeping Units (SKUs) and more than 300 products, including tablets (plain, enteric-coated, and film-coated), hard & soft gelatin capsules, oral liquids, and ointments. In the USA, the company operates through its wholly-owned subsidiary, Time Cap Labs Inc, acquired in June 2015, catering to major retailers like Target, Walmart, Walgreens, and Kroger with a range of Private Label OTC and Generic Prescription Drugs.

Marksans Pharma Share Price Prediction 2024 – 2030

Marksans Pharma Share Price Target 2024

When	Maximum Price	Minimum Price
August 2024	214.65	186.66
September 2024	223.24	194.12
October 2024	218.86	190.32
November 2024	227.62	197.93
December 2024	229.89	199.91

In 2024, Marksans Pharma’s projected prices are as follows: In August, the maximum price is projected to be ₹214.65, with a minimum of ₹186.66. By December, the projected maximum price Projected to rise ₹229.89, while the minimum price is expected to be ₹199.91.

Marksans Pharma Share Price Target 2025

When	Maximum Price	Minimum Price
January 2025	232.19	178.61
February 2025	234.54	180.41
March 2025	239.46	184.20
April 2025	237.09	182.38
May 2025	230.19	177.07
June 2025	240.55	185.03
July 2025	235.83	181.41
August 2025	243.12	187.02
September 2025	246.04	189.26
October 2025	252.44	194.18
November 2025	258.75	199.04
December 2025	270.39	207.99

In 2025, Marksans Pharma’s projected prices are as follows: In January, the maximum price is expected to be ₹232.19, with a minimum of ₹178.61. By December, the projected maximum price will reach ₹270.39, while the minimum price is anticipated to be ₹207.99.

Marksans Pharma Share Price Target 2026

When	Maximum Price	Minimum Price
January 2026	278.50	214.23
February 2026	271.54	208.88
March 2026	276.97	213.05
April 2026	282.62	217.40
May 2026	279.83	215.25
June 2026	286.82	220.63
July 2026	281.20	216.31
August 2026	289.89	223.00
September 2026	295.69	227.46
October 2026	303.38	233.37
November 2026	310.96	239.20
December 2026	318.74	245.18

Marksans Pharma Share Price Target 2027

When	Maximum Price	Minimum Price
January 2027	321.93	247.64
February 2027	330.18	253.98
March 2027	343.06	263.89
April 2027	336.33	258.72
May 2027	326.53	251.18
June 2027	341.23	262.48
July 2027	334.54	257.34
August 2027	344.88	265.30
September 2027	356.96	274.58
October 2027	366.24	281.72
November 2027	375.39	288.76
December 2027	384.78	295.98

Marksans Pharma Share Price Target 2028

When	Maximum Price	Minimum Price
January 2028	392.47	301.90
February 2028	402.54	309.64
March 2028	418.23	321.72
April 2028	410.03	315.41
May 2028	398.09	306.22
June 2028	416.01	320.00
July 2028	407.85	313.73
August 2028	420.46	323.43
September 2028	435.18	334.75
October 2028	446.49	343.46
November 2028	457.66	352.04
December 2028	469.10	360.84

Marksans Pharma Share Price Target 2029

When	Maximum Price	Minimum Price
January 2029	478.48	368.06
February 2029	490.75	377.50
March 2029	509.89	392.22
April 2029	499.89	384.53
May 2029	485.33	373.33
June 2029	507.17	390.13
July 2029	497.22	382.48
August 2029	512.60	394.31
September 2029	530.54	408.11
October 2029	544.34	418.72
November 2029	557.95	429.19
December 2029	571.89	439.92

Marksans Pharma Share Price Target 2030

When	Maximum Price	Minimum Price
January 2030	583.33	448.72
February 2030	598.29	460.22
March 2030	621.62	478.17
April 2030	609.43	468.80
May 2030	591.68	455.14
June 2030	618.31	475.62
July 2030	606.19	466.30
August 2030	624.93	480.72
September 2030	646.81	497.54
October 2030	663.62	510.48
November 2030	680.21	523.24
December 2030	697.22	536.32

In 2030, Marksans Pharma’s projected prices are as follows: In January, the maximum price is expected to be ₹583.33, with a minimum of ₹448.72. By December, the projected maximum price will reach ₹697.22, while the minimum price is anticipated to be ₹536.32.

Financial Condition of Marksans Pharma: Last 5 Years

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Equity Capital	41	41	41	45	45
Reserves	595	846	1,068	1,700	2,020
Borrowings +	30	34	111	123	244
Other Liabilities +	236	307	416	322	372
Total Liabilities	902	1,228	1,636	2,190	2,681
Fixed Assets +	303	309	428	486	780
CWIP	0	12	3	10	5
Investments	0	0	0	1	27
Other Assets +	599	907	1,205	1,694	1,869
Total Assets	902	1,228	1,636	2,190	2,681

Marksans Pharma’s financial data from March 2020 to March 2024 reveals a significant upward trend in key metrics. The company’s equity capital remained steady at ₹41 crore from March 2020 to March 2021, before increasing to ₹45 crore by March 2023 and March 2024. Reserves have shown robust growth, rising from ₹595 crore in March 2020 to ₹2,020 crore by March 2024.

Borrowings increased moderately from ₹30 crore in March 2020 to ₹244 crore in March 2024, indicating expanded financial leverage. Other liabilities experienced fluctuations, with a peak of ₹416 crore in March 2022 and settling at ₹372 crore by March 2024.

Total liabilities grew significantly from ₹902 crore in March 2020 to ₹2,681 crore by March 2024, reflecting Marksans Pharma’s expanded operations and financial obligations. Fixed assets increased notably from ₹303 crore to ₹780 crore over the period, suggesting substantial investment in infrastructure and capacity.

The company’s total assets expanded from ₹902 crore in March 2020 to ₹2,681 crore in March 2024, driven by higher fixed assets and an increase in other assets, which grew from ₹599 crore to ₹1,869 crore. This growth underscores Marksans Pharma’s ongoing investments and expansion strategies, reinforcing its strong financial positioning and growth trajectory.

FAQs